- Home
- ALLT vs MNPR Comparison
ALLT vs MNPR Comparison
Compare ALLT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLT | MNPR |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 506.5M | 421.0M |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ALLT | MNPR |
|---|---|---|
| Price | $10.30 | $70.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $13.25 | ★ $101.42 |
| AVG Volume (30 Days) | ★ 417.4K | 335.5K |
| Earning Date | 02-24-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $98,512,000.00 | N/A |
| Revenue This Year | $12.08 | N/A |
| Revenue Next Year | $12.38 | N/A |
| P/E Ratio | $478.96 | ★ N/A |
| Revenue Growth | ★ 7.51 | N/A |
| 52 Week Low | $4.37 | $26.06 |
| 52 Week High | $11.92 | $105.00 |
Technical Indicators
Market Signals| Indicator | ALLT | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 51.88 |
| Support Level | $10.70 | $61.65 |
| Resistance Level | $11.04 | $66.65 |
| Average True Range (ATR) | 0.59 | 5.68 |
| MACD | -0.05 | 1.24 |
| Stochastic Oscillator | 39.46 | 85.21 |
Price Performance
Historical ComparisonAbout ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.